Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

171 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Plasma Aβ42/Aβ40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease.
Rissman RA, Langford O, Raman R, Donohue MC, Abdel-Latif S, Meyer MR, Wente-Roth T, Kirmess KM, Ngolab J, Winston CN, Jimenez-Maggiora G, Rafii MS, Sachdev P, West T, Yarasheski KE, Braunstein JB, Irizarry M, Johnson KA, Aisen PS, Sperling RA; AHEAD 3-45 Study team. Rissman RA, et al. Among authors: yarasheski ke. Alzheimers Dement. 2024 Feb;20(2):1214-1224. doi: 10.1002/alz.13542. Epub 2023 Nov 6. Alzheimers Dement. 2024. PMID: 37932961 Free PMC article.
Plasma Aβ42/Aβ40 Ratios in Older People With Human Immunodeficiency Virus.
Cooley SA, Nelson B, Boerwinkle A, Yarasheski KE, Kirmess KM, Meyer MR, Schindler SE, Morris JC, Fagan A, Ances BM, O'Halloran JA. Cooley SA, et al. Among authors: yarasheski ke. Clin Infect Dis. 2023 May 24;76(10):1776-1783. doi: 10.1093/cid/ciad001. Clin Infect Dis. 2023. PMID: 36610788 Free PMC article.
Plasma Aβ42/40 and cognitive variability are associated with cognitive function in Black Americans: Findings from the AA-FAIM cohort.
Fischer B, Van Hulle CA, Langhough R, Norton D, Zuelsdorff M, Gooding DC, Wyman MF, Johnson A, Lambrou N, James T, Bouges S, Carter FP, Salazar H, Kirmess K, Holubasch M, Meyer M, Venkatesh V, West T, Verghese P, Yarasheski K, Carlsson CM, Johnson SC, Asthana S, Gleason CE. Fischer B, et al. Alzheimers Dement (N Y). 2023 Sep 25;9(3):e12414. doi: 10.1002/trc2.12414. eCollection 2023 Jul-Sep. Alzheimers Dement (N Y). 2023. PMID: 37752907 Free PMC article.
Associations of sleep duration and daytime sleepiness with plasma amyloid beta and cognitive performance in cognitively unimpaired, middle-aged and older African Americans.
Cook JD, Malik A, Plante DT, Norton D, Langhough Koscik R, Du L, Bendlin BB, Kirmess KM, Holubasch MS, Meyer MR, Venkatesh V, West T, Verghese PB, Yarasheski KE, Thomas KV, Carlsson CM, Asthana S, Johnson SC, Gleason CE, Zuelsdorff M. Cook JD, et al. Among authors: yarasheski ke. Sleep. 2024 Jan 11;47(1):zsad302. doi: 10.1093/sleep/zsad302. Sleep. 2024. PMID: 38011629 Free PMC article.
The Bio-Hermes Study: Biomarker database developed to investigate blood-based and digital biomarkers in community-based, diverse populations clinically screened for Alzheimer's disease.
Mohs RC, Beauregard D, Dwyer J, Gaudioso J, Bork J, MaGee-Rodgers T, Key MN, Kerwin DR, Hughes L, Cordell CB; Bio‐Hermes Collaborative Group. Mohs RC, et al. Alzheimers Dement. 2024 Apr;20(4):2752-2765. doi: 10.1002/alz.13722. Epub 2024 Feb 28. Alzheimers Dement. 2024. PMID: 38415908 Free PMC article.
Clinical validation of the PrecivityAD2 blood test: A mass spectrometry-based test with algorithm combining %p-tau217 and Aβ42/40 ratio to identify presence of brain amyloid.
Meyer MR, Kirmess KM, Eastwood S, Wente-Roth TL, Irvin F, Holubasch MS, Venkatesh V, Fogelman I, Monane M, Hanna L, Rabinovici GD, Siegel BA, Whitmer RA, Apgar C, Bateman RJ, Holtzman DM, Irizarry M, Verbel D, Sachdev P, Ito S, Contois J, Yarasheski KE, Braunstein JB, Verghese PB, West T. Meyer MR, et al. Among authors: yarasheski ke. Alzheimers Dement. 2024 May;20(5):3179-3192. doi: 10.1002/alz.13764. Epub 2024 Mar 16. Alzheimers Dement. 2024. PMID: 38491912 Free PMC article.
Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimer's disease trial.
Molina-Henry DP, Raman R, Liu A, Langford O, Johnson K, Shum LK, Glover CM, Dhadda S, Irizarry M, Jimenez-Maggiora G, Braunstein JB, Yarasheski K, Venkatesh V, West T, Verghese PB, Rissman RA, Aisen P, Grill JD, Sperling RA. Molina-Henry DP, et al. Alzheimers Dement. 2024 Jun;20(6):3827-3838. doi: 10.1002/alz.13803. Epub 2024 Apr 17. Alzheimers Dement. 2024. PMID: 38629508 Free PMC article.
Unexpected Low Rate of Amyloid-β Pathology in Multiple Sclerosis Patients.
Brier MR, Schindler SE, Salter A, Perantie D, Shelley N, Judge B, Keefe S, Kirmess KM, Verghese PB, Yarasheski KE, Venkatesh V, Raji CA, Gordon BA, Bateman RJ, Morris JC, Naismith RT, Holtzman DM, Benzinger TLS, Cross AH. Brier MR, et al. Among authors: yarasheski ke. Ann Neurol. 2024 Sep;96(3):453-459. doi: 10.1002/ana.27027. Epub 2024 Jul 4. Ann Neurol. 2024. PMID: 38963256
The AlzMatch Pilot Study - Feasibility of Remote Blood Collection of Plasma Biomarkers for Preclinical Alzheimer's Disease Trials.
Walter S, Langford O, Jimenez-Maggiora GA, Abdel-Latif S, Rissman RA, Grill JD, Karlawish J, Atri A, Bruschi S, Hussen K, Donohue MC, Marshall GA, Jicha G, Racke M, Turner RS, van Dyck CH, Venkatesh V, Yarasheski KE, Sperling R, Cummings J, Aisen PS, Raman R. Walter S, et al. Among authors: yarasheski ke. J Prev Alzheimers Dis. 2024;11(5):1435-1444. doi: 10.14283/jpad.2024.101. J Prev Alzheimers Dis. 2024. PMID: 39350391 Free PMC article.
171 results